期刊文献+

急性心肌梗死患者PCI术中冠脉内注射替罗非班对TIMI血流的影响 被引量:2

Effect of tirofiban intracoronary injection on TEMI flow in patients with AMI during emergency percutaneous coronary intervention
下载PDF
导出
摘要 目的 分析ST段抬高型急性心肌梗死(STEMI)患者急诊经皮冠状动脉介入治疗(PCI)术中,冠脉内注射盐酸替罗非班对梗死相关血管冠脉血流(TIMI)的影响.方法 选择2006年1月至2008年12月在我院住院的STEMI患者100例,随机分为2组,均于发病12 h内行PCI术.治疗组PCI术中立即将替罗非班按10μg/kg剂量用生理盐水稀释成20 ml,冠脉内3 min注射完毕,静脉维持量0.15μg·kg-1·min-136 h.对照组PCI术中静脉负荷量0.4 μg·kg-1·min-130 min,维持量0.15 μg·kg-1·min-136 h.20 min后复查冠脉造影,评价梗死相关血管TIMI血流、术后4周并发症及主要不良心脏事件的发生情况.结果 治疗组术中冠脉内注射替罗非班,PCI术后TIMI血流Ⅱ级发生率低于对照组(7.7%比22.9%,P=0.033),TIMI血流Ⅲ级高于对照组(92.3%比75.0%,P=0.018),术后4周主要不良心脏事件的发生率低于对照组(5.8%比18.8%,P=0.046),差异有统计学意义(P<0.05),出血并发症的发生与对照组差异无统计学意义(13.5%比12.5%,P=0.886).结论 STEMI患者急诊PCI术中冠脉内应用盐酸替罗非班能改善梗死相关血管的TIMI血流,减少PCI术后无复流、慢复流的发生率及术后4周主要不良心脏事件的发生率,不增加出血并发症的发生,临床应用安全有效.
出处 《中国心血管病研究》 CAS 2009年第7期491-493,共3页 Chinese Journal of Cardiovascular Research
  • 相关文献

参考文献6

二级参考文献23

  • 1王同汉,刘映峰,李志梁,魏向龙,石向东.急性心肌梗死伴心衰、心源性休克病人经皮冠状动脉介入治疗近中期疗效[J].第一军医大学学报,2005,25(8):1064-1066. 被引量:8
  • 2杨新春,徐立,王乐丰,葛永贵,王红石,丁枭伟,王文君,邹阳春,李惟铭,刘宇.国产替罗非班对急性心肌梗死患者急诊介入治疗术后冠状动脉血流和心肌灌注影响的研究[J].中国循环杂志,2006,21(1):4-7. 被引量:91
  • 3Furber AP, Prunier F, Nguyen HC, et al.Coronary blood flow assessment after successful angioplasty for acute myocardial infarction predicts the risk of long I term cardiac events [ J ]. Circulation, 2004, 110 (23) :3527 - 3533.
  • 4Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thromholysis in myocardial infarction perfusion grade after coronary angioplasty in patients with acute anterior wall myocardial infarction[J]. Circulation, 1996, 93( 11 ) :1933 - 1999.
  • 5Michaels AD, Gibson CM, Barron HV. Microvascular dysfunction in acute myocardial infarction: focus on the role of platelet and in flammatory medialors in the no-reflow phenomenon[J]. Am J Cardiol, 2000, 85(54) :50B -60B.
  • 6The RESTORE Investigators. Effects of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction underging coronary angioplasty[ J]. Circulation, 1997, 96(5) : 1445 - 1453.
  • 7Montalescot G, Borentain M, Payot L, et al. Early vs late administration of glycoprotein Ⅱb/Ⅲa inhibition in primary pewutaneous coronary intervention of acute ST-segment elevation myocardial infarction :A meta-analysis[J]. JAMA, 2004, 292(3):362-366.
  • 8Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation, 2002,105 : 656-662.
  • 9Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein Ⅱ b/Ⅲ a blockade with primary PTCA Organization and Randomized Trial ( RAPPORT ). Circulation, 1998,98 : 734-741.
  • 10Montalescot G, Barragan P, Wittenberg O, et al. For the ADMIRAL Investigators. Platelet glycoprotein Ⅱ b/Ⅲ a inhibition with coronary stenting for acute myocardial infarction. N Eng J Med, 2001, 344:1895-1903.

共引文献165

同被引文献31

  • 1陈玉善,刘鹏,张燕,关怀敏.早期应用替罗非班对急性心肌梗死患者直接PCI疗效的初步观察[J].中国心血管病研究,2007,5(10):734-736. 被引量:6
  • 2Ho H, Taniyama Y, Lwakum K, et al. Intravenous nieorandil call preserve microvascular integrity and myocardial viability in patients tllreperfusedanterior wall myocardial infaretion. J Am Coil Cardiol, 1999,33 : 654-660.
  • 3Elmouchi DA, Bates ER. Platelet glyeoprote [ Ⅱb/Ⅲ a in bibitor therapy in non ST segment elevation acute coronary syndromes. Minerva Cardioangiol, 2003,51 : 547-560.
  • 4ocardial infarfion:a report of the American College of Cardiology/ American Heart Association Task Force on Pnlctiee Guidelines (Committee to Revise the 1999 Guide-lines for the Management of Patients with Acute myocardial infarfion). Circulation,2004, 110 : e82-92.
  • 5Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. J Am Coil Cardiol, 2007,50 : 2173-2195.
  • 6Siber S, Albertsson P, Ariles EF, et al. Guidelines for percu- tananeons coromary interventions. The Task for Percutaneons coromary intervention of the European Society of Cardiology. Eur Heart, 2005,26 : 804-847.
  • 7Rezkalla SH, Kloncr RA. No-flow phenonenon. Circulation, 2002,105:656-662.
  • 8Hekzer T, Ollmann T, Koke K, et al. Platelet glycoprotein Ⅱ b/ Ⅲ a receptor blockade improves vascular nitric oxide bioavailabili-ty in patients with coronary artery disease. Circulation,2003, 108 : 530-541.
  • 9Warnhohz A, Ostad MA, Heitzer T, et al. Effect of tirofiban on percutaneous coronary intervention-induced endothebat dysfunc- tion in patients with stable coronary artery disease. Am J Cardiol, 2005,95 : 20-23.
  • 10Marfinez-Rlos MA, Rosas M, Gonzalez H, et al. Comparison of repeffusion regimens with or without tirofiban in ST-elevation acute myoeardla. Am J Cardiol, 2004,93 : 280-287.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部